



# A micro-sterile inflammation array as an adjuvant for influenza vaccines

## Citation

Ji, Wang, Dilip Shah, Xinyuan Chen, R. Rox Anderson, and Mei X. Wu. 2015. "A micro-sterile inflammation array as an adjuvant for influenza vaccines." *Nature communications* 5 (1): 4447. doi:10.1038/ncomms5447. <http://dx.doi.org/10.1038/ncomms5447>.

## Published Version

doi:10.1038/ncomms5447

## Permanent link

<http://nrs.harvard.edu/urn-3:HUL.InstRepos:15034938>

## Terms of Use

This article was downloaded from Harvard University's DASH repository, and is made available under the terms and conditions applicable to Other Posted Material, as set forth at <http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAA>

## Share Your Story

The Harvard community has made this article openly available.  
Please share how this access benefits you. [Submit a story](#).

[Accessibility](#)



Published in final edited form as:

Nat Commun. ; 5: 4447. doi:10.1038/ncomms5447.

## A micro-sterile inflammation array as an adjuvant for influenza vaccines

Wang Ji<sup>1</sup>, Dilip Shah<sup>1</sup>, Xinyuan Chen<sup>1</sup>, R. Rox Anderson<sup>1,2</sup>, and Mei X. Wu<sup>1,2,†</sup>

<sup>1</sup>Wellman Center for Photomedicine, Massachusetts General Hospital (MGH), Department of Dermatology, Harvard Medical School (HMS), Boston, MA

<sup>2</sup>Harvard-MIT Division of Health Sciences and Technology (HST), Cambridge, MA

### Abstract

There is an urgent need of adjuvants for cutaneous vaccination. Here we report that micro-sterile inflammation induced at inoculation sites can augment immune responses to influenza vaccines in animal models. The inoculation site is briefly illuminated with a handheld, non-ablative fractional laser before the vaccine is intradermally administered, which creates an array of self-healing microthermal zones (MTZs) in the skin. The dying cells in the MTZs send “danger” signals that attract a large number of antigen-presenting cells, in particular, plasmacytoid dendritic cells (pDCs) around each MTZ forming a micro-sterile inflammation array. A pivotal role for pDCs in the adjuvanticity is ascertained by significant abrogation of the immunity after systemic depletion of pDCs, local application of a TNF- $\alpha$  inhibitor, or null mutation of IFN regulatory factor7 (IRF7). In contrast to conventional adjuvants that cause persistent inflammation and skin lesions, micro-sterile inflammation enhances efficacy of influenza vaccines, yet with diminished adverse effects.

### Introduction

We have made tremendous progress in the past decade in understanding sterile inflammation, which is induced by danger signals released from dying cells as a natural response to invaders or injuries in order to protect our body<sup>1</sup>. The danger signals, known as damage-associated molecular patterns (DAMPs), include uric acid, dsDNA, RNA, and others, and they can attract and activate antigen presenting cells (APCs). The sterile inflammation is one of the primary mechanisms behind aluminum salt, also called alum, and MF59 adjuvants, two licensed vaccine adjuvants, and forms the basis for today’s adjuvant development<sup>2–6</sup>. The ability of sterile inflammation to augment immune responses against vaccines raises an intriguing possibility that skin injury can serve as an “adjuvant” for cutaneous vaccination, provided that the injury is well under control. Non-ablative fractional laser (NAFL) can controllably injure the dermis at the site of vaccine inoculation. The laser

<sup>†</sup>Address Correspondence to: Dr. Mei X. Wu, Wellman Center for Photomedicine, Massachusetts General Hospital, 50 Blossom Street, Edwards 222, Boston, MA 02114, TEL: 617-726-1298; FAX: 617-726-1206; mwu2@partners.org.

#### Author contributions

M.X.W. has designed and supervised the research. J.W., D.S., X.Y.C. designed and performed the experiments. R.R.A. helped the idea and participated in manuscript writing. M.X.W., J.W., D.S., X.Y.C. wrote the manuscript.

The authors have no conflict of interest to declare.

treatment generates an array of self-renewable micro-thermo zones (MTZs) in a desirable number, size, and depth without damaging skin's outer protective layer, so that skin barrier function can be well preserved<sup>7</sup>. Each MTZ is so small that it can heal within days by fast-growing epithelial cells surrounding each MTZ, resulting in younger-looking skin<sup>7-10</sup>. NAFL technology is a mature industry for dermatologic treatment applications<sup>7</sup>. The micro-skin injury sharply contrasts with the injury induced by intradermal (ID) injection of adjuvants that often evokes severe and persistent inflammation and overt skin lesions, making them not acceptable for routine vaccination<sup>11</sup>. However, whether this fast healing micro-injury in the skin is sufficient to strengthen immune responses has not been yet explored.

Skin is prone to adjuvant-induced inflammation, which causes severe local reactogenicity including erythema, swelling, and ulceration that can persist for weeks<sup>11</sup>. Because of these unwanted adverse events, most current adjuvants such as alum, oil-in-water emulsion adjuvants, and several agonists of Toll-like receptor (TLR) are not suitable for skin vaccination<sup>11</sup>. If we are to take advantages of cutaneous vaccination as a more efficient route over conventional intramuscular (IM) immunization, effective adjuvants that do not cause overt skin inflammation are an urgent need<sup>12-15</sup>.

We present here that NAFL induces sterile inflammation at a micro-scale that causes no overt skin lesions while greatly augmenting immune responses to influenza vaccines ID administered. The danger signals released by dying cells in laser-generated MTZs preferably attract plasmacytoid dendritic cells (pDCs) that are subsequently activated by topically applied imiquimod (IMI) cream, an agonist for TLR-7<sup>16</sup>, leading to synergistic augmentation of the immune response against influenza vaccine in adult and old mice as well as in pigs.

## Results

### NAFL/IMI adjuvant augments immune responses provoked by influenza vaccines

An over-the-counter, handheld, cosmetic NAFL generated a 6×9 array of 54 MTZs, in a 7 mm×10 mm rectangular area of the skin as illustrated in Supplementary Fig. 1 a, b. Each MTZ was a thermal injury about the size and shape of a hair, approximately 200 μm in diameter and 300 μm in depth. The MTZs heal quickly, giving rise to new and younger skin<sup>17</sup>. The sterile inflammation induced by laser-damage cells was restricted around each MTZ, leaving a majority of tissues unaffected, warranting a quick resolution of the inflammation. To test whether this transient, micro-scale inflammation was sufficient to augment immunity stimulated by various vaccines, a clinical H1N1 influenza vaccine (A/California/7/2009) was ID inoculated into the site of laser illumination. As shown in Fig. 1a, hemagglutinin inhibition (HAI) antibody titers were significantly higher in the presence as compared to the absence of laser treatment ( $p<0.05$ , ANOVA/Bonferroni). There was a slightly greater immune response evoked with ID than IM immunization, similar to previous investigations (Fig. 1a)<sup>12, 13, 18</sup>. Comparable results were also attained with the protein model antigen ovalbumin (OVA), hepatitis B surface antigen vaccine (HBsAg) or recombinant influenza HA protein (rHA), raising specific antibody titers by 6- ( $p<0.001$ ,  $t$ -test), 10- ( $p<0.05$ ,  $t$ -test) and 3- ( $p<0.01$ ,  $t$ -test) fold, respectively (Supplementary Fig. 1c, d,

e). The adjuvant effect of NAFL was primarily ascribed to laser-mediated cell damage. Hence, when influenza vaccine was mixed with a small number of heat (65°C or 95°C)-damaged skin cells and ID administered, the heat-damaged cells enhanced immune responses against the co-injected influenza vaccine at a level comparable to that of laser treatment ( $p<0.01$  for 65°C and  $p<0.05$  for 95°C, ANOVA/Bonferroni, Supplementary Fig 2). Moreover, the laser illumination conferred similar adjuvant effects as that of topical IMIQ cream (Aldara®, 3M Pharmaceuticals) which is a FDA approved topical drug for treatment of some skin diseases (Fig. 1a) <sup>19</sup>. Strikingly, when laser-treated skin was inoculated with the influenza vaccine, followed by topical application of IMIQ cream, the combination synergistically enhanced HAI titers by 7-fold or 4-fold over IM or ID vaccination, respectively (Fig. 1a,  $p<0.001$ , ANOVA/Bonferroni). This robust response was greater than that induced by IM immunization of a 10× higher amount of the vaccine, suggesting at least 10× dose-sparing over the current IM influenza vaccination (Fig. 1a). Similar trends were attained in total serum IgG and IgA levels (Fig. 1b, c). The adjuvant effect was also confirmed in outbred Swiss Webster mice in which IgG and HAI titers were greatly higher with laser pre-illumination than without the illumination (Supplementary Fig. 3).

In humans, a majority of people are primed with influenza viral antigens either via vaccination or natural infections. To test if the NAFL or NAFL/IMIQ adjuvant could boost the immune response efficiently in antigen-primed subjects, mice were primed with H1N1 influenza vaccine with or without NAFL or NAFL/IMIQ, followed by an immunization booster two weeks later. As expected, the adjuvant boosted the immune response in primed subjects as effectively as in naïve ones, regardless of whether the primary vaccination was given influenza vaccine alone or the vaccine in combination with NAFL or NAFL/IMIQ adjuvant (Supplementary Fig. 4).

Measurement of serum IgG1 and IgG2a antibody titers revealed Th1-skewed immune responses in the presence of NAFL/IMIQ adjuvant. The adjuvant elevated IgG2a production by 15-fold, and only a 5-fold increase was seen with IMIQ alone (Fig. 1d,  $p<0.001$ , ANOVA/Bonferroni). In contrast, NAFL alone stimulated mainly IgG1 production with barely detectable IgG2a, indicative of Th2 immune responses. Apparently, topical application of IMIQ cream on the NAFL-treated site is not simply a combination of Th2 and Th1 responses, rather converting it into a stronger Th1 immune response that is required for more effective protection against viral infection (Supplementary Fig. 5a, b).

The superior humoral immune response at a high HAI titer of more than 1:100 was sustained for at least 9 months without any sign of decline (Fig. 1e), a period of time longer than an influenza season which typically lasts for 6 months in the most part of the world. NAFL alone was also able to retain a HAI titer above the standard protective level (1:40) for more than 9 months (Fig. 1e). In comparison, topical IMIQ was not as strong as NAFL in sustaining HAI production, and the HAI titer started to decline after 3 months of immunization and reached similar levels as non-adjuvanted influenza vaccine 3 more months later (Fig. 1e). Alongside, the IgG level in NAFL/IMIQ group was also substantially higher than that of other groups throughout the entire experimental period (Supplementary Fig. 5c). Not only humoral, but cellular immune responses were also greatly improved by NAFL/IMIQ adjuvant. The percentages of CD8<sup>+</sup> and CD4<sup>+</sup> T cells secreting IFN- $\gamma$  in the

periphery were vigorously increased only in the NAFL/IMIQ group among all groups tested after influenza viral stimulation (Fig. 1f, g,  $p < 0.001$  or  $0.01$  ANOVA/Dunnett's).

### Enhanced protection against viral infection

The immunized mice were challenged with a mouse-adapted A/California/7/2009 H1N1 virus. The NAFL/IMIQ adjuvant greatly reduced lung viral titer to  $2.2 \times 10^1$  PFU per 1 mg tissue ( $p < 0.001$ , ANOVA/Bonferroni), which was 1,000 times lower than that attained in mice receiving the vaccine alone (Fig. 1h). Moreover, the body weight dropped by more than 17% in 8 days post-infection in all groups except for the NAFL/IMIQ group (Fig. 1i). The latter showed a decline in their body weight at the slowest pace, yet recovered at the fastest pace (Fig. 1i). All mice died within 8 days in non-immunized controls or mice immunized similarly without any adjuvant (Fig. 1j). Four out of 6 mice died in IMIQ group and 2 out of 8 died in the NAFL group, whereas all mice survived in the NAFL/IMIQ group (Fig. 1j). Similar results were obtained in Swiss Webster mice showing substantial reduction of influenza viral replication in the lung of animals immunized with H1N1 influenza vaccine in the presence of the NAFL/IMIQ adjuvant as compared to the vaccine alone (Supplement Fig. 3c,  $p < 0.001$ , ANOVA/Bonferroni).

### Comparisons between NAFL/IMIQ and a squalene-based adjuvant

NAFL/IMIQ adjuvant was further compared with AddaVax<sup>®</sup> (Invivogen), which has a similar formulation and physical/chemical feature as MF59<sup>4</sup>. IM inoculation of influenza vaccine emulsified with an equal amount of AddaVax provoked immune responses slightly inferior to those of the NAFL/IMIQ adjuvant, as measured by IgG and HAI titers (Fig. 2a, b), suggesting that the laser-based adjuvant is equal to or somewhat better than this specific squalene-based adjuvant in augmentation of influenza vaccines. However, NAFL/IMIQ caused no overt skin lesions at the inoculation site, although mild inflammation was noticed in one day and disappeared within 3 days with histological examination (Fig. 2c **right panel**). Similar to previous investigation<sup>17</sup>, small-diameter, thermally coagulated columns were generated in dermis by the laser, with intact stratum corneum and epidermis in place (Fig. 2c **right panel**). In contrast, IM administration of AddaVax mixed with influenza vaccine caused inflammation that persisted for more than one week (Fig. 2c **left panel**). Moreover, NAFL/IMIQ induced a much lower level of pro-inflammatory cytokine responses systemically as manifested by a relatively lower level of circulating IL-6, an important mediator of fever (Fig. 2d). IL-6 concentration peaked after 8 hours of immunization and reached as high as  $134 \text{ pg ml}^{-1}$  in mice receiving the squalene-adjuvanted influenza vaccine, which was 4 times higher than the  $32 \text{ pg ml}^{-1}$  IL-6 seen in mice immunized by the same amount of vaccines with the NAFL/IMIQ adjuvant (Fig. 2d,  $p < 0.01$  *t*-test). Besides, the squalene-adjuvanted vaccine elevated the body temperature by  $1^\circ\text{C}$  that lasted for 9 hours, when compared with mice receiving the vaccine alone (Fig 2e). In sharp contrast, no fever was measurable over the influenza vaccine alone in the NAFL/IMIQ group (Fig 2e). The safety profile requires further confirmation with licensed MF59 in place of commercial AddaVax in future study.

## Safety and effectiveness in swine

Safety and potency of the adjuvant were further evaluated in swine because porcine skin resembles human skin in term of anatomy, skin reactogenicity, immune responses, and pharmacokinetics<sup>20</sup>. Since the skin of pigs is thicker than mice, we used a higher power cosmetic NAFL, named Fraxel SR-1500 (Solta Medical) for pig studies. After one pass of the laser treatment, the pigs were ID vaccinated with 3 µg HA of 2009 H1N1 vaccine, equivalent to a full dose of ID influenza vaccine in humans on the basis of body weight. The immunization enhanced HAI titers by ~2-fold compared to ID vaccine alone (Fig. 3a). The laser treatment also increased the production of HBsAg-specific antibodies by more than 5~7-fold in both primary and booster immunizations (Supplementary Fig. 6). Topical IMIQ further enhanced the immunogenicity in pigs, similarly as described in mice (Fig. 3a), but remarkably, concurred with diminished local skin reactogenicity. As shown in Fig. 3b, **1<sup>st</sup> column**, ID influenza vaccine caused wheals with a diameter of 0.5–1 cm right after immunization, concomitant with significant erythema and swelling at the injection site, which peaked on day 3 and resolved by day 7 post-immunization, similar to what has been described in humans<sup>21,22</sup>. In comparison with influenza vaccine alone, similar or less skin reaction was observed at the injection site immediately (day 0, < 30 minutes) or days 1 and 3 after immunization at laser-treated site (Fig. 3b **2<sup>nd</sup> column**). Diminished skin irritation was further appreciated on days 1 and 3 by combination of NAFL and IMIQ (Fig. 3b **4<sup>th</sup> column**), in sharp contrast to the peaking skin irritation seen in the ID group during the same period of time (Fig. 3b **1<sup>th</sup> column**). The milder skin reactogenicity was measured by 50% reduction in the mean area of erythema at the inoculation site in the NAFL/IMIQ group as compared to the influenza vaccine alone group (Fig. 3c, 11 vs. 23 mm<sup>2</sup>,  $p < 0.001$ , ANOVA/Bonferroni). In parallel, histology examination of the inoculation sites confirmed drastic diminishment of infiltrated inflammatory cells in pigs receiving influenza vaccine adjuvanted by NAFL/IMIQ as compared to the pigs receiving influenza vaccine alone (Fig. 3d).

## The mechanism of action of NAFL/IMIQ adjuvant

To determine the underlying mechanism, we tracked MHC II<sup>+</sup> cells at the inoculation site with or without laser treatment in mice expressing MHC II infused with green fluorescent protein (GFP)<sup>23</sup>. The MHC II<sup>+</sup> cells in the skin are mainly DCs, Langerhans cells, and macrophages, broadly defined as APCs<sup>24, 25</sup>. An increase in the motility of APCs was noticed soon after laser treatment and these cells were gradually recruited to the vicinity of MTZs. Their accumulation around individual MTZs became apparent as early as 3 hours and peaked 24 hours after laser illumination (Fig. 4a, **upper panel**). As expected, the MTZ induced recruitment of APCs was well separated spatially (Fig. 4a, **left panel**). To our surprise, IMIQ did not augment, but rather reduced NAFL-induced accumulation of APCs around the MTZs (Fig. 4a, **lower panel**), raising a possibility that IMIQ might promote migration of APCs. In an attempt to address this, whole mount histology of the inoculation site was performed to determine entrances of APCs into lymphatic vessels. It was found that the number of GFP<sup>+</sup> cells in lymphatic vessels was significantly elevated by IMIQ and to a lesser extent, by NAFL, but it was the combination that led to the highest number of APCs entering into the lymphatic vessels among all the groups at all time points tested (Fig. 4b, c).



Consistent with the highest number of GFP<sup>+</sup> cells in the lymphatic vessels was the lowest percentage of CD11c<sup>+</sup> DCs in the skin, in parallel to a corresponding increase in the number of CD11c<sup>+</sup> DCs in the draining lymph nodes (dLNs) in mice receiving the vaccine and NAFL/IMIQ adjuvant (Fig. 4d, e). Accelerated migration of APCs to dLNs may be crucial on two fronts: (1) augmentation of influenza vaccine-induced immunity and (2) reduction of local inflammation because a smaller number of mature APCs at the inoculation site can facilitate inflammation resolution, whereas a higher number of mature DCs in dLNs are pivotal for heightened immune responses.

We also found that CD11c<sup>+</sup> cells only accumulated in ipsilateral, but not in contralateral, lymph nodes indicating that the adjuvant effects of NAFL/IMIQ impacts locally rather than systemically (Supplementary Fig. 7). Therefore we focused on local events to investigate synergistic adjuvant effects of NAFL and IMIQ. The active recruitment of APCs around each MTZ promoted us to study local chemokine production stimulated by NAFL treatment. Six out of nine chemokines examined were elevated 6 hours after NAFL treatment, peaked in 24 hours, and dwindled down thereafter (Fig. 5a), in agreement with resolving inflammation at the inoculation site in 2 days (Fig. 2c). Among these chemokines, CCL2, CCL20, CXCL9, CXCL10, CXCL12 and Chemerin are known to preferably attract pDCs<sup>26–29</sup>. pDCs, characterized as CD11c<sup>+</sup>CD11b<sup>–</sup>B220<sup>+</sup>Ly6C<sup>+</sup>PDCA-1<sup>+</sup> cells (Supplementary Fig. 8a), accumulated at the inoculation site at a level 4-time higher after 24 hours of NAFL treatment when compared to non-laser-treated skin (Fig. 5b). The pDC recruitment was further enhanced by topic IMIQ leading to an 8-fold increase in the percentage of pDCs at the inoculation site (Fig. 5b and Supplementary Fig. 8b). The pDCs mainly accumulated in the vicinity of MTZs as evidenced by strong immunohistological staining around each MTZ with an antibody against a pDC-specific marker, Siglec H (Fig. 5c, **upper**). NAFL/IMIQ might also attract other immune cells, but pDCs were preferable targets of IMIQ because of a high level of TLR7 expression on the cells<sup>30</sup>. Preferable mobilization of pDCs explained a relatively high level of IFN- $\alpha/\beta$ , TNF- $\alpha$ , and IL-6 at the inoculation site 6 hours after the immunization in the presence of NAFL/IMIQ adjuvant (Fig. 5d), since pDCs, but not conventional DCs, produced high levels of these proinflammatory cytokines upon activation by IMIQ (Supplementary Fig. 9). In contrast, IMIQ alone failed to vigorously increase the expression of these cytokines under similar conditions, in agreement with previous investigation<sup>27</sup>.

Among these cytokines induced at the inoculation site, TNF- $\alpha$  has been demonstrated to promote migration of dermal DCs into dLNs<sup>31</sup>. We thus ID injected a TNF- $\alpha$  inhibitor, soluble TNF-Receptor Type I (TNF RI) into the inoculation site following the immunization. The TNF- $\alpha$  inhibitor hampered adjuvant effects of NAFL/IMIQ, in particular, on IgG2a production ( $p < 0.001$ ,  $t$ -test), highlighting a critical role for TNF- $\alpha$  in NAFL/IMIQ-mediated adjuvanticity (Supplementary Fig. 10a). Moreover, Th1-biased adjuvanticity of NAFL/IMIQ was significantly impaired in mice deficient in interferon regulatory factor 7 (IRF7) (Supplementary Fig. 10b,  $p < 0.05$   $t$ -test), suggesting contribution of IFN- $\alpha/\beta$ , two major activators of immature DCs, to the immune-enhancement of NAFL/IMIQ as well<sup>32</sup>. This Th1-predominant cytokine milieu at the inoculation site was pivotal for increasing percentages (Supplementary Fig. 11, 12a and 12b) and numbers (Fig. 5e, f) of

CD40<sup>+</sup> and CD86<sup>+</sup> mature CD11c<sup>+</sup> DCs in dLNs in the presence of NAFL/IMIQ. The increase in mature DCs was also corroborated with a relatively high mean fluorescent intensity (MFI) of CD40 and CD86 staining on the cells (Supplementary Fig. 12a, b). Notably, the percentages of CD40<sup>+</sup> and CD86<sup>+</sup> DCs arose significantly in the IMIQ group at 6 or 18 hours or in the NAFL group at 6 hours after immunization, but the total number of mature DCs in dLNs were much more prominent in the NAFL/IMIQ group, which translated into a strong acquired immunity in the animals (Fig. 5e, f and Supplementary Fig. 12). Strikingly, not all proinflammatory cytokines were synergistically elevated by NAFL/IMIQ, and rather, IL-1 family (IL-1 $\alpha/\beta$ , IL-18, IL-33) and thymic stromal lymphopoietin (TSLP) were diminished considerably as compared to mice immunized with the vaccine alone, or along with either topical IMIQ or NAFL (Fig. 5d). The selective decrease in these mediators may be another reason behind a limited local reaction in the presence of NAFL/IMIQ, because both IL-1 family and TSLP are mediators of local inflammation and dermatitis as demonstrated by a number of studies<sup>33, 34</sup>.

To directly address a pivotal role of pDCs in the synergistic adjuvant effect of NAFL and IMIQ, we depleted pDCs in Balb/c mice by injection of anti-mPDCA-1 antibody prior to immunization<sup>35</sup>. pDC depletion did not affect IgG1 levels, but profoundly impaired IgG2a production in the NAFL/IMIQ group (Fig. 5g **upper panel**,  $p < 0.01$   $t$ -test). In addition to diminished production of IgG2a, pDC depletion compromised cell-mediated immune responses as well, reflected by significant decreases in the percentages of CD4<sup>+</sup> and CD8<sup>+</sup> T cells secreting IFN- $\gamma$  (Fig. 5g **middle and lower panels**,  $p < 0.01$   $t$ -test). Interestingly, the impairment was not evidenced in the IMIQ group indicating that the effect of topical IMIQ relied primarily on dermal resident APCs, because pDCs were almost undetectable in normal, non-laser-treated skin<sup>36</sup>. In contrast to IMIQ, pDC depletion resulted in a significant decrease in the percentages of both CD4<sup>+</sup> ( $p < 0.01$   $t$ -test) and CD8<sup>+</sup> T ( $p < 0.05$   $t$ -test) cells producing IFN- $\gamma$  in mice immunized with NAFL-adjuvanted influenza vaccine (Fig. 5g). The results argue strongly that NAFL-mediated recruitment of pDCs into the inoculation site is key for the observed adjuvant effect of NAFL/IMIQ.

### Increasing influenza vaccine-induced immune responses in aged mice

Given the strong cell-mediated immune response evoked by the new adjuvant, we extended our investigation to old mice, because elderly people respond poorly to current seasonal influenza vaccines. Unfortunately, the elderly suffer from a high level of morbidity and mortality after influenza viral infection and need the vaccine most. As shown in Fig. 6a and Supplementary Fig. 13, old BALB/c mice elicited a rather weak immune response compared with that of adult mice after IM immunization with H1N1 influenza vaccine alone. The weak immune response of the old mice was not improved by ID vaccination regardless of whether NAFL or IMIQ was employed. In contrast, the combination of NAFL/IMIQ adjuvant elicited vigorous humoral ( $p < 0.001$ , ANOVA/Dunnett's) and cellular ( $p < 0.01$ , ANOVA/Dunnett's) immune responses in these old animals (Fig. 6a–c and Supplementary Fig. 13a). The levels of humoral and cell-mediated responses were arguably greater than those provoked by AddaVax adjuvanted influenza vaccine or in adult mice IM immunized with the same amount of the influenza vaccine (Fig. 6a–c,  $p < 0.01$ , ANOVA/Dunnett's). Similar to what occurred in adult mice, the NAFL/IMIQ adjuvant increased pDCs in number



at the inoculation site and provoked primarily Th1 immune response in old mice as suggested by a higher ratio of IgG2a to IgG1 and greater percentages of IFN- $\gamma$ -producing CD8<sup>+</sup> and CD4<sup>+</sup> T cells in the presence vs. the absence of NAFL/IMIQ adjuvant (Fig. 6b, c, Supplementary Fig. 13b, c). As a result, ~80% (10/13) of the old mice were protected from lethal H1N1 viral infection after ID immunization of the influenza vaccine with the NAFL/IMIQ adjuvant, which was superior to the 17% (1/6) protection only in the mice IM immunized with squalene-adjuvanted influenza vaccine (Fig. 6d, e). There was no protection against the viral challenge if the animals were ID immunized with influenza vaccine alone or along with either adjuvant (Fig. 6d, e).

## Discussion

Many vaccine adjuvants are being developed in preclinical studies or in various stages of clinical trials and the potency of these conventional adjuvants often comes at the expense of safety<sup>37</sup>. The current investigation explores a novel adjuvant that limits adverse effects locally and systemically, while augmenting efficacy of influenza vaccines in both small and large animal models and in young and old mice. The hand-held, NAFL device we used is self-applicable and FDA approved for facial wrinkle removal at home, which requires a higher safety standard than laser illumination of a tiny spot on the upper arm used for vaccination in a medical office. The laser parameters in our swine study are well below those normally used in a clinical practice for skin resurfacing, and can be readily incorporated into the existing design of the small device. The 1410 nm light works in a stamp/scanning fashion and is equally effective regardless of skin color, in contrast to the 532 nm laser adjuvant described previously<sup>38,39</sup>. Its microprobe is tightly sealed by a thin plastic that prevents any skin materials from contaminating the probe, and the sealer is readily cleaned aseptically to prevent person-to-person contamination. The laser does not damage the stratum corneum, the skin's most outlayer of epidermis, so that integrity of the skin barrier is preserved<sup>17</sup>. Another advantage of this adjuvant is its standalone feature, like a topical adjuvant, which means there is no requirement for pre-mixture or re-formulation to use it with existing or new vaccines. The adjuvant can also be readily incorporated into portable and/or self-vaccination procedures with various needle-free, painless, microneedle-array patches.

IMIQ cream (Aldara®) was initially approved by FDA more than 15 years ago as a topical treatment for genital/perianal warts at age 12 or older. The drug has also been approved for treatment of superficial basal cell carcinoma and actinic keratosis as of 2004. In those treatments, the cream is applied three times a week for up to 12 weeks or daily for several weeks, and in many cases a relatively large area of the skin is affected<sup>19</sup>. In contrast, for use as an adjuvant along with NAFL, IMIQ is topically applied only once to a skin area of smaller than 1 cm<sup>2</sup>, so the systemic absorption or local reaction is extremely limited<sup>40</sup>. In this preclinical study, we showed that a combination of NAFL and topical IMIQ apparently alleviates, rather than worsens, skin irritation provoked by influenza vaccine in pigs. NAFL/IMIQ not only blunts local inflammation but also raises little circulating IL-6 or body fever over influenza vaccines. In contrast, a fever was clearly presented along with a significantly higher level of IL-6 in mice receiving IM vaccination of squalene-adjuvanted vaccines.

Whether or not this safer profile demonstrated in mice can translate into humans remains to be investigated.

The mechanisms underlying the ability of NAFL/IMIQ adjuvant to augment influenza vaccine while reducing adverse events are likely to be multifaceted. As depicted in Supplementary Fig. 14, laser-damaged cells in each MTZ release danger signals that stimulate the production of a number of chemokines and preferably attract pDCs from circulation leading to their increased presence around each MTZ. These pDCs are then activated by IMIQ penetrating from the skin surface because the cells express a high level of TLR7. Upon activation pDCs secrete TNF- $\alpha$ , IFN- $\alpha/\beta$  and the like, and these cytokines direct maturation and differentiation of APCs *in situ*, and accelerate trafficking of these mature APCs into dLNs via lymphatic vessels<sup>31, 32</sup>. Therefore, NAFL-induced recruitment and IMIQ-mediated activation are likely to be the primary mechanisms for the observed synergy of these two adjuvants, resulting in a high level of TNF- $\alpha$  secretion at the inoculation site. An essential part of TNF- $\alpha$  in maturation and migration of dermal DCs into dLNs was clearly demonstrated by the ability of TNF- $\alpha$  inhibitor to impede immune enhancement of NAFL/IMIQ. Moreover, Cumberbatch *et al.* showed that ID injection of TNF- $\alpha$  evoked a concentration and time- dependent maturation and trafficking of dermal DCs into dLNs<sup>41</sup>. On the contrary, mice deficient in TNF- $\alpha$  receptor had impaired DC maturation after bacterial infection<sup>42</sup>. Besides TNF- $\alpha$ , IFN- $\alpha/\beta$  produced by pDCs also contributed to a high level of Th1 immunity evoked by NAFL/IMIQ. In IRF7 deficient mice whose pDCs could not produce IFN- $\alpha/\beta$  efficiently<sup>43</sup>, IgG2a production was diminished significantly, in agreement with a recent investigation<sup>44</sup>. Moreover, depletion of pDCs almost completely blunted the adjuvant effect of NAFL/IMIQ on IgG2a production and on cell-mediated immune responses.

Another major finding of this investigation is that micro sterile inflammation induced by NAFL occurs only briefly, peaking at 24 hours and subsiding in 48 hours, but this short period of local sterile inflammation appears enough to “educate” DCs in bridging an innate to adaptive immune response. These findings are consistent with previous investigations demonstrating that prolonged inflammation induced by alum was dispensable for its adjuvanticity<sup>45</sup>. Surgical removal of the inoculation site containing alum 2 hours after vaccination did not affect the adjuvanticity of alum<sup>45</sup>, an argument strongly supported by the current investigation. Besides a shortened period of local inflammation, infiltration of pDCs may also contribute to the reduced skin irritation, as Gregorio *et al* reported that pDCs could rapidly infiltrate into skin in response to skin injury, and improve the skin recovery<sup>36</sup>. Finally, a combination of laser and IMIQ selectively reduces the production of the cytokines of the IL-1 family and TSLP that are well known to contribute to the local skin irritation<sup>33,34</sup>, which may be another mechanism for reducing local and systemic adverse events of this topical adjuvant.

Inflammatory effects of an ideal adjuvant should be localized and transient, which is particularly important for cutaneous vaccination<sup>46</sup>. The finding that a strong immune response can be provoked by transient micro-sterile inflammation at the inoculation site is of highly clinical significance for cutaneous vaccination. A growing body of evidence has shown that cutaneous vaccination is more effective than IM vaccination, as the skin is

enriched in APCs and in networks of lymphatic vessels, in contrast to the muscle where few APCs reside. However, severe skin lesions caused by various adjuvants, hamper a broad application of this route of immunization, apart from inconvenience. Therefore, this micro-sterile inflammation based adjuvant merits clinical investigations for dose-sparing or augmenting the efficacy of influenza vaccines in certain high-risk groups like the elderly. Furthermore, this approach may raise fewer concerns of long-term safety, because only vaccine itself is injected into the body.

## Methods

### Animals

Inbred BALB/c mice and outbred Swiss Webster mice at 6~8 weeks of age were purchased from Charles River Laboratories. Mice of both genders were used randomly with no notable difference. Eighteen-month-old BALB/c mice (old mice) were purchased from National Institute of Aging (NIA). Irf7<sup>-/-</sup> mice on C57BL/6J background were a kindly gift of Dr T. Taniguchi, Tokyo University<sup>43</sup> and C57BL/6J control mice were obtained from Jackson Laboratories. MHC II-EGFP mice expressing MHC class II molecule infused into enhanced green fluorescent protein (GFP) were a kindly gift of Drs. Boes and Ploegh, Harvard Medical School<sup>23</sup>. Male Yorkshire pigs at 4 months of age were obtained from the Teaching and Research Resources at Tufts University. The animals were housed in the specific pathogen free animal facilities of Massachusetts General Hospital (MGH) in compliance with institutional, hospital, and NIH guidelines. All studies were reviewed and approved by the MGH Institutional Animal Care and Use Committee.

### Laser adjuvant

A FDA-approved, home-use NAFL laser was used in mice (PaloVia<sup>®</sup> Skin Renewing Laser, Palomar Medical Technologies). The hand-held device emits a 1410-nm laser light and two passes at the medium power were used to generate overlapped MTZs at the inoculation site. Pigs were treated with one pass of Fraxel SR-1500 laser (Solta Medical). This clinical device emitted an array of laser with 17% coverage, 93 MTZs cm<sup>-2</sup> per pass, and 35mJ per microbeam.

### Influenza virus and vaccine

Pandemic A/California/7/2009 H1N1 influenza virus was obtained from American Type Culture Collection (ATCC, #FR-201). The virus was expanded in 10-day-old embryonated chicken eggs at 35°C for 3 days, harvested by ultracentrifugation, and frozen at -80°C until use. Its quantity was determined with a 50% tissue culture infectious dose (TCID<sub>50</sub>) in Madin-Darby canine kidney cells (MDCK, ATCC, #CCL-34). To challenge mice, the virus was adapted in mice for three cycles of intranasal instillation-lung homogenate preparation and infectivity of the resultant virus was assayed by a 50% lethal dose (LD<sub>50</sub>) in adult BALB/c mice following a standard protocol. Monovalent A/California/7/2009 H1N1 influenza vaccine (Sanofi Pasteur, Inc.) was obtained from MGH pharmacy and BEI Resources, used at 0.06 µg HA per mouse or 3 µg HA per pig unless otherwise indicated.

## Immunizations and challenges

Mice to be immunized were hair removed on the lower dorsal skin and ID inoculated on the next day with influenza vaccine or illuminated with laser before the vaccine was ID administered. After ID immunization, the inoculation site was either left alone or topically applied with imiquimod cream (IMIQ) (Aldara<sup>®</sup>, 3M Pharmaceuticals). The inoculation site was then covered with a 3M Tegaderm film to protect it. For IM injection of adjuvanted influenza vaccine, AddaVax<sup>®</sup>, a squalene based nano-emulsion adjuvant (Invivogen) with a formulation similar to licensed MF59 adjuvant, was mixed with influenza vaccine at 1:1 ratio and IM injected in a total volume of 20  $\mu$ l. Body temperature was monitored hourly in some of the mice by a temperature control device (FHC). Blood cytokines were measured by enzyme-linked immunosorbent assay (ELISA) kit (eBiosciences). The immunized and control mice were challenged by intranasal instillation of 10 $\times$  LD<sub>50</sub> mouse-adapted 2009 H1N1 viruses. Body weight and survival were monitored daily for 14 days unless otherwise specified. In some infection experiments, lungs were harvested 4 days after challenge to measure lung viral titers by TCID<sub>50</sub> assays. To immunize pigs, the animals were anesthetized by IM injection of telazol (2.2 mg kg<sup>-1</sup>)/xylazine (2.2 mg kg<sup>-1</sup>)/atropine (0.04mg kg<sup>-1</sup>) and maintained under isoflurane (2–3%) inhalation during hair removal and immunization. Immunization procedure was similar as described in mice with 100  $\mu$ l influenza vaccine (3  $\mu$ g HA content) inoculated into the exterior hind leg skin either alone or in the presence of NAFL, IMIQ, or NAFL/IMIQ adjuvant. To quantify local skin reactions, the inoculation sites were photographed and the erythema area at each inoculation site was circled and analyzed by Image Pro Premier software (Media Cybernetics, Inc) for 3 times with which mean erythema area of each inoculation site was calculated.

## HAI assay

HAI titers were assayed according to a published protocol (PMID: 19274084). Serum samples were incubated with receptor-destroying enzyme (RDE) (Denka Seiken) at 37°C overnight followed by heat inactivation at 56°C for 30 minutes. The resultant serum samples were incubated with 4 hemagglutination (HA) units of influenza virus at 37°C for 1 hour after serial dilutions, and then with 0.5% chicken red blood cells (Charles River Laboratories) at room temperature for 30 minutes. The HAI titer was defined as the reciprocal of the highest dilution that inhibited hemagglutination.

## ELISA

Vaccine-specific IgG, IgG1, IgG2a and IgA antibody titers were measured by ELISA. In brief, 1  $\mu$ g ml<sup>-1</sup> recombinant HA was coated onto ELISA plates in NaHCO<sub>3</sub> buffer, pH9.6. After incubation with serially diluted serum samples, HRP-conjugated goat anti-mouse IgG (NA931V, GE healthcare, dilution 1:6000), IgG1 (A90-105P, Bethyl, dilution 1:10000), IgG2a (61-0220, Life Technologies, dilution 1:2000) or IgA (A90-103P, Bethyl, 1:10000) antibody was added to measure specific subtypes. For C57BL/6 mice, anti-mouse IgG2c (1079-05, Southern Biotech, 1:5000) antibody was used in place of anti-IgG2a antibody.

### Cell-mediated immune responses

One week after immunization, blood samples were collected from immunized and control mice in a heparinized tube by tail vein bleeding. Peripheral blood mononuclear cells (PBMCs) were isolated after red blood cell lysis. PBMCs ( $10^6$  cells per ml) were incubated with influenza vaccine ( $1 \mu\text{g ml}^{-1}$  HA content) and anti-CD28 (clone 37.51, BD Pharmingen,  $4 \mu\text{g ml}^{-1}$ ) antibody overnight. Golgi-Plug (BD Pharmingen) was added to prevent cytokine secretion in the final 5 hours of the incubation. The stimulated cells were stained with fluorescence-conjugated antibodies against CD4 (clone RM4-5, Biolegend, dilution 1:100), CD8 (clone 53-6.7, Biolegend, dilution 1:200), and IFN $\gamma$  (clone XMG1.2, Biolegend, 1:100), followed by flow cytometric analysis as previously reported<sup>47</sup>.

### Histological examination

Mice were ID immunized with influenza vaccine in the presence of NAFL/IMIQ adjuvant or IM with the vaccine mixed with AddaVax. The tissues at the inoculation site were dissected at indicated days, fixed and stained by a standard H&E procedure. Similar histological examination was also carried out in pigs after 3 days of immunization. The slides were scanned and analyzed by NanoZoomer (Hamamatsu).

### Intravital confocal imaging

The ear of MHC II-EGFP transgenic mice was treated by NAFL or NAFL/IMIQ. GFP<sup>+</sup> cells in the epidermis and dermis were imaged by intravital two-photon confocal microscopy (Olympus FV-1000). Three-D reconstruction was used to visualize accumulation of GFP<sup>+</sup> cells around individual MTZs by Image J software.

### Whole mount immune histology

The ear of MHC II-EGFP transgenic mice was inoculated with influenza vaccine in the presence of the indicated adjuvants. The outer ear flaps were prepared at indicated times post-immunization, fixed by 4% formaldehyde at 4 °C overnight, and blocked by 2% FBS/PBS for 2 hours at room temperature. The fixed samples were reacted with rat anti-LYVE-1 (clone 223322, R&D systems,  $8 \mu\text{g ml}^{-1}$ ) antibody to identify lymphatic vessels and rabbit anti-Collagen IV (ab6586, Abcam,  $10 \mu\text{g ml}^{-1}$ ) antibody at 4°C overnight to label both lymphatic and blood vessels, after which the samples were stained with Cy3-conjugated anti-rat (A10522, Life Technology, dilution 1:100) and NL637-conjugated anti-rabbit (NL005, R&D systems, dilution 1:100) antibodies at 4°C overnight. The stained samples were mounted and imaged by two-photon confocal microscopy (Olympus FV-1000).

### Immunohistological analysis of pDCs

The lower dorsal skin of mice was exposed to NAFL/IMIQ adjuvant. Twenty four hours later, full thickness of the skin at the site of laser illumination was excised, and frozen tissue sections were prepared and labeled by anti-mouse Siglec H (clone 440c, eBioscience,  $10 \mu\text{g ml}^{-1}$ ) or isotype control antibody followed by staining with DL594-conjugated goat anti-rat IgG (SA5-10081, Thermo Pierce, dilution 1:100) antibody. The slides were mounted with a

mount medium containing a nuclear staining fluorescence dye of DAPI and imaged by confocal microscopy.

### Analysis of dermal DCs or pDCs by flow cytometry

Skin at the inoculation site was excised, minced, and digested with Dispase II (Life Technologies) and Collagenase D (Roche) for 2 hour at 37°C. The digested skin tissues were passed through a 100 µm cell strainer to prepare single cell suspensions. The resultant cells were treated with anti-CD16/CD32 antibody (clone 93, Biolegend, dilution 1:50) for 20 minutes, followed by staining with the following fluorescence-conjugated antibodies for 30 minutes on ice: APC-anti-PDCA-1(clone 927, dilution 1:300), PE-anti- CD11c (clone N418, eBioscience, dilution 1:100), BV421-anti-CD11b (clone M1/70, dilution 1:100), FITC-anti-MHCII (clone M5/114.15.2, dilution 1:200), FITC- anti-Ly6C (clone HK1.4, dilution 1:200), and APC/Cy7-anti-B220 (clone RA3-6B2, dilution 1:100). All antibodies were purchased from Biolegend unless otherwise stated. The stained cells were acquired on a FACS Aria (BD) and analyzed using FlowJo software (Tree Star).

### In vivo depletion of pDCs

Balb/c mice were intraperitoneally (IP) injected with two doses of anti-mPDCA-1 antibody (clone JF05-1C2.4.1, Miltenyi Biotec) at 400 µg per dose at 24 and 0 hours, respectively, before immunization<sup>35</sup>. Depletion efficiency was confirmed by flow cytometry of pDCs in the blood samples. Effects of pDC depletion on cellular immune responses were evaluated one week later, and humoral immune responses were analyzed two weeks after the immunization.

### Quantification of DCs in dLNs

dLNs were collected and single-cell suspensions were prepared, counted, stained with FITC-anti-CD11c (clone N418, eBiosciences, dilution 1:100), APC-anti-CD40 (clone 3/23, Biolegend, dilution 1:100) and PerCp-Cy5.5-anti-CD86 (clone GL-1, Biolegend, dilution 1:100) antibodies, followed by flow cytometry. Total numbers of CD11c<sup>+</sup> cells, CD40<sup>+</sup>CD11c<sup>+</sup> cells or CD86<sup>+</sup> CD11c<sup>+</sup> cells per lymph node were calculated in the basis of the total number of cells and percentages of each cell subset in the lymph node.

### Quantitative real-time PCR

To analyze chemokine and inflammatory cytokine expression at the inoculation site, the full thickness of the skin area about 7×10 mm<sup>2</sup> was excised, and total RNA was extracted, reverse-transcribed, and amplified by qPCR using a SYBR Green PCR kit (Roche). GAPDH was used as an internal control. All genes and their primers were listed in Supplementary Table 1.

### Statistical analysis

Two tailed t-test (*t*-test) was used to analyze a difference between two groups, and one way ANOVA was used among multiple groups. ANOVA followed by Bonferroni correction (ANOVA/Bonferroni) was used to compare selected pairs, and ANOVA followed by Dunnett's test (ANOVA/Dunnett's) was for comparing all groups with a control group. p



value was calculated by PRISM software (GraphPad) and a difference was regarded significant if p value was less than 0.05. Sample sizes were designed based on preliminary experiments to give statistical power. No animals were excluded from the analysis. The investigators were not blinded to the experiments which were carried out under highly standardized and predefined conditions, except for photo analysis and H&E slide examination that were performed in an investigator-blind fashion.

## Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

## Acknowledgments


The authors would like to thank Margaret Sherwood, Jenny Zhao and Danny Cao for their help in the microscopy and flow cytometry during this project. This work is supported in part by the National Institutes of Health grants AI089779, AI070785, AI097696, and DA028378 (to M.X.W.) and Bullock-Wellman Fellowship and A. Ward. Ford. Memorial Grant NSP0511 (to X.Y.C).

## Reference

1. Chen GY, Nunez G. Sterile inflammation: sensing and reacting to damage. *Nat Rev Immunol.* 2010; 10:826. [PubMed: 21088683]
2. Marichal T, et al. DNA released from dying host cells mediates aluminum adjuvant activity. *Nat Med.* 2011; 17:996. [PubMed: 21765404]
3. Kool M, et al. Alum adjuvant boosts adaptive immunity by inducing uric acid and activating inflammatory dendritic cells. *J Exp Med.* 2008; 205:869. [PubMed: 18362170]
4. O'Hagan DT, Ott GS, De Gregorio E, Seubert A. The mechanism of action of M59. *Vaccine.* 2012; 30:4341. [PubMed: 22682289]
5. McKee AS, et al. Host DNA released in response to aluminum adjuvant enhances MHC class II-mediated antigen presentation and prolongs CD4 T-cell interactions with dendritic cells. *Proc Natl Acad Sci U S A.* 2013; 110:E1122–E1131. [PubMed: 23447566]
6. Eisenbarth SC, Colegio OR, O'Connor W, Sutterwala FS, Flavell RA. Crucial role for the Nalp3 inflammasome in the immunostimulatory properties of aluminium adjuvants. *Nature.* 2008; 453:1122. [PubMed: 18496530]
7. Manstein D, Herron GS, Sink RK, Tanner H, Anderson RR. Fractional photothermolysis: a new concept for cutaneous remodeling using microscopic patterns of thermal injury. *Lasers Surg Med.* 2004; 34:426. [PubMed: 15216537]
8. Tajirian AL, Goldberg DJ. Fractional ablative laser skin resurfacing: a review. *J Cosmet Laser Ther.* 2011; 13:262. [PubMed: 22091797]
9. Saedi N, Petelin A, Zachary C. Fractionation: a new era in laser resurfacing. *Clin Plast Surg.* 2011; 38:449. vii. [PubMed: 21824542]
10. Alexiades-Armenaka M, Sarnoff D, Gotkin R, Sadick N. Multi-center clinical study and review of fractional ablative CO2 laser resurfacing for the treatment of rhytides, photoaging, scars and striae. *J Drugs Dermatol.* 2011; 10:352. [PubMed: 21455544]
11. Chen X, Wu MX. Laser vaccine adjuvant for cutaneous immunization. *Expert Rev Vaccines.* 2011; 10:1397. [PubMed: 21988305]
12. Kenney RT, Frech SA, Muenz LR, Villar CP, Glenn GM. Dose sparing with intradermal injection of influenza vaccine. *N Engl J Med.* 2004; 351:2295. [PubMed: 15525714]
13. Belshe RB, et al. Serum antibody responses after intradermal vaccination against influenza. *N Engl J Med.* 2004; 351:2286. [PubMed: 15525713]
14. Fishbein DB, et al. Rabies preexposure prophylaxis with human diploid cell rabies vaccine: a dose-response study. *J Infect Dis.* 1987; 156:50. [PubMed: 3598225]

15. Pancharoen C, et al. Reduced-dose intradermal vaccination against hepatitis A with an aluminum-free vaccine is immunogenic and can lower costs. *Clin Infect Dis*. 2005; 41:1537. [PubMed: 16231271]
16. Gibson SJ, et al. Plasmacytoid dendritic cells produce cytokines and mature in response to the TLR7 agonists, imiquimod and resiquimod. *Cell Immunol*. 2002; 218:74. [PubMed: 12470615]
17. Leyden J, Stephens TJ, Herndon JH Jr. Multicenter clinical trial of a home-use nonablative fractional laser device for wrinkle reduction. *J Am Acad Dermatol*. 2012; 67:975. [PubMed: 22386051]
18. Arnou R, et al. Intradermal influenza vaccine for older adults: a randomized controlled multicenter phase III study. *Vaccine*. 2009; 27:7304. [PubMed: 19849996]
19. Gupta AK, Cherman AM, Tying SK. Viral and nonviral uses of imiquimod: a review. *J Cutan Med Surg*. 2004; 8:338. [PubMed: 15868314]
20. Monteiro-Riviere, NA.; Riviere, J. The Pig As a Model for Cutaneous Pharmacology and Toxicology Research. In: Tumbleson, ME.; Schook, BM., editors. *Advances in Swine in Biomedical Research*. New York: Springer US; 1996. p. 425-458.
21. Beran J, et al. Intradermal influenza vaccination of healthy adults using a new microinjection system: a 3-year randomised controlled safety and immunogenicity trial. *BMC Med*. 2009; 7:13. [PubMed: 19341446]
22. Leroux-Roels I, et al. Seasonal influenza vaccine delivered by intradermal microinjection: A randomised controlled safety and immunogenicity trial in adults. *Vaccine*. 2008; 26:6614. [PubMed: 18930093]
23. Boes M, et al. T-cell engagement of dendritic cells rapidly rearranges MHC class II transport. *Nature*. 2002; 418:983. [PubMed: 12198548]
24. Batista FD, Harwood NE. The who, how and where of antigen presentation to B cells. *Nat Rev Immunol*. 2009; 9:15. [PubMed: 19079135]
25. Itano AA, Jenkins MK. Antigen presentation to naive CD4 T cells in the lymph node. *Nat Immunol*. 2003; 4:733. [PubMed: 12888794]
26. Vanbervliet B, et al. The inducible CXCR3 ligands control plasmacytoid dendritic cell responsiveness to the constitutive chemokine stromal cell-derived factor 1 (SDF-1)/CXCL12. *J Exp Med*. 2003; 198:823. [PubMed: 12953097]
27. Drobits B, et al. Imiquimod clears tumors in mice independent of adaptive immunity by converting pDCs into tumor-killing effector cells. *J Clin Invest*. 2012; 122:575. [PubMed: 22251703]
28. Sisirak V, et al. CCR6/CCR10-mediated plasmacytoid dendritic cell recruitment to inflamed epithelia after instruction in lymphoid tissues. *Blood*. 2011; 118:5130. [PubMed: 21937703]
29. Skrzeczynska-Moncznik J, et al. Potential role of chemerin in recruitment of plasmacytoid dendritic cells to diseased skin. *Biochem Biophys Res Commun*. 2009; 380:323. [PubMed: 19168032]
30. Kawai T, Akira S. TLR signaling. *Cell Death Differ*. 2006; 13:816. [PubMed: 16410796]
31. Alvarez D, Vollmann EH, von Andrian UH. Mechanisms and consequences of dendritic cell migration. *Immunity*. 2008; 29:325. [PubMed: 18799141]
32. Theofilopoulos AN, Baccala R, Beutler B, Kono DH. Type I interferons (alpha/beta) in immunity and autoimmunity. *Annu Rev Immunol*. 2005; 23:307. [PubMed: 15771573]
33. Jensen LE. Targeting the IL-1 family members in skin inflammation. *Curr Opin Investig Drugs*. 2010; 11:1211.
34. Soumelis V, et al. Human epithelial cells trigger dendritic cell mediated allergic inflammation by producing TSLP. *Nat Immunol*. 2002; 3:673. [PubMed: 12055625]
35. Krug A, et al. TLR9-dependent recognition of MCMV by IPC and DC generates coordinated cytokine responses that activate antiviral NK cell function. *Immunity*. 2004; 21:107. [PubMed: 15345224]
36. Gregorio J, et al. Plasmacytoid dendritic cells sense skin injury and promote wound healing through type I interferons. *J Exp Med*. 2010; 207:2921. [PubMed: 21115688]
37. Petrovsky N, Aguilar JC. Vaccine adjuvants: current state and future trends. *Immunol Cell Biol*. 2004; 82:488. [PubMed: 15479434]

38. Chen X, et al. A novel laser vaccine adjuvant increases the motility of antigen presenting cells. *PLoS ONE*. 2010; 5:e13776. [PubMed: 21048884]
39. Chen X, Pravetoni M, Bhayana B, Pentel PR, Wu MX. High immunogenicity of nicotine vaccines obtained by intradermal delivery with safe adjuvants. *Vaccine*. 2012; 31:159. [PubMed: 23123021]
40. Cantisani C, et al. Imiquimod 5% cream use in dermatology, side effects and recent patents. *Recent Pat Inflamm Allergy Drug Discov*. 2012; 6:65. [PubMed: 22185454]
41. Cumberbatch M, Kimber I. Dermal tumour necrosis factor-alpha induces dendritic cell migration to draining lymph nodes, and possibly provides one stimulus for Langerhans' cell migration. *Immunology*. 1992; 75:257. [PubMed: 1551688]
42. Sundquist M, Wick MJ. TNF-alpha-dependent and -independent maturation of dendritic cells and recruited CD11c(int)CD11b<sup>+</sup> Cells during oral Salmonella infection. *J Immunol*. 2005; 175:3287. [PubMed: 16116221]
43. Honda K, et al. IRF-7 is the master regulator of type-I interferon-dependent immune responses. *Nature*. 2005; 434:772. [PubMed: 15800576]
44. Koyama S, et al. Plasmacytoid dendritic cells delineate immunogenicity of influenza vaccine subtypes. *Sci Transl Med*. 2010; 2 25ra24.
45. Hutchison S, et al. Antigen depot is not required for alum adjuvanticity. *FASEB J*. 2012; 26:1272. [PubMed: 22106367]
46. Reed SG, Orr MT, Fox CB. Key roles of adjuvants in modern vaccines. *Nat Med*. 2013; 19:1597. [PubMed: 24309663]
47. Hong DK, et al. Cationic lipid/DNA complex-adjuvanted influenza A virus vaccination induces robust cross-protective immunity. *J Virol*. 2010; 84:12691. [PubMed: 20943978]



**Figure 1. NAFL/IMIQ strengthens immunogenicity of ID influenza vaccine**

BALB/c mice were ID immunized with 0.06  $\mu$ g (HA content) H1N1 influenza vaccine alone (no adjuvant) or in the presence of NAFL, IMIQ, or NAFL/IMIQ adjuvant or IM immunized with a same dose (IM) or a 10 $\times$  higher dose (0.6  $\mu$ g) of the vaccine. Humoral immune responses were measured 4 weeks later including HAI titer (a), IgG (b), IgA (c) or IgG2a (d). HAI titers were further monitored at 4, 12, 24, and 36 weeks post immunization (e). A horizontal gray line indicates a standard protective titer of HAI. n=8, except for NAFL and NAFL/IMIQ groups (n=10). (f, g) Cell-mediated immune responses. PBMCs were isolated one week after immunization, stimulated with the vaccine and anti-CD28 antibody and analyzed for the percentages of IFN $\gamma$ -secreting CD8<sup>+</sup> (f) and CD4<sup>+</sup> (g) T cells by flow cytometry. n=6, except for NAFL and NAFL/IMIQ groups (n=8). (h-j) Challenge studies. The immunized mice and non-immunized controls were intranasally challenged with 10 $\times$  LD<sub>50</sub> of A/California/7/2009 H1N1 virus 5 weeks post-immunization. The infected mice were euthanized 4 days post-infection to determine lung viral titers by TCID<sub>50</sub> assays using MDCK cells (h). n=6. Body weight (i) and survival (j) were monitored daily for 14 days. Percentages of body weight dropped relative to a pre-infection level and percentages of survivals were compared between NAFL/IMIQ and NAFL or IMIQ groups by *t*-test or


Logrank test respectively.  $n=6$ , except for NAFL and NAFL/IMIQ groups ( $n=8$ ). Data are presented as mean  $\pm$  s.e.m. Statistical significance was analyzed by ANOVA/Bonferroni unless noted otherwise. \*,  $p<0.05$ ; \*\*,  $p<0.01$  or \*\*\*,  $p<0.001$ , respectively. All experiments were repeated twice with similar results.

Author Manuscript

Author Manuscript

Author Manuscript


Author Manuscript



**Figure 2. Comparison of NAFL/IMIQ with a squalene-based adjuvant**


BALB/c mice were ID immunized with influenza vaccine alone (no adjuvant) or in the presence of NAFL/IMIQ adjuvant, or IM immunized with a same dose of the vaccine mixed with squalene-based adjuvant (AddaVax). Serum IgG (**a**) and HAI (**b**) levels were measured in 2 weeks.  $n=8$ . (**c**) H&E staining of inoculation sites. Muscle and skin tissues of the inoculation sites were collected on days 1, 3, and 7, and shown are representative results of 4 similar experiments performed. Arrows and black dash lines indicate part of a MTZ, scale bar, 100  $\mu\text{m}$ . Note: stratum corneum (SC) and epidermis (Epi) are in place after laser treatment. Serum IL-6 was measured at 0, 1, 4, 8, 24, and 48 hours after immunization by ELISA (**d**) and body temperature was monitored hourly for 10 hours (**e**). All temperatures were normalized to non-immunized mice.  $n=4$ . Data are presented as mean  $\pm$  s.e.m. Statistical significance was analyzed by ANOVA/Bonferroni for (**a**) and (**b**), or t-test for (**d**) and (**e**). \*,  $p<0.05$ ; \*\*,  $p<0.01$  or \*\*\*,  $p<0.001$ , respectively. The experiments were repeated twice with similar results, unless noted otherwise.






**Figure 3. NAFL/IMIQ adjuvant in swine study**

The exterior hind legs of yorkshire pigs were shaved, cleaned and ID vaccinated with 100  $\mu$ l of the influenza vaccine (3  $\mu$ g HA content) only (no adjuvant) or following one pass of laser illumination with Fraxel SR-1500 (NAFL), after which IMIQ was applied to the immunization site (NAFL/IMIQ). Alternatively, the immunization site receiving the vaccine alone was topically applied with IMIQ directly (IMIQ). HAI titers were measured in 2 weeks **(a)**. Each symbol represents data from individual animals, horizontal bars indicate mean, and a dish line marks the standard protective titer of HAI. n=4. **(b)** Photos were taken right (day 0) and 1, 3, and 7 days after immunization and representative results were shown with 4 pigs in each group. Scale bar, 5 mm. **(c)** The erythema areas of injection sites were analyzed by Image Pro Premier software 3 days after immunization. Each symbol represents a mean value of one injection site analyzed for 3 times. Horizontal bars indicate the mean. From left to right, n=11, 8, 8, and 12, respectively. **(d)** H&E slides showing infiltrated cells at the inoculation site, representative of 6 similar results in two separate experiments. Scale bar, 200  $\mu$ m. Statistical significance was analyzed by ANOVA/Bonferroni. \*, p<0.05; \*\*, p<0.01 or \*\*\*, p<0.001, respectively.



**Figure 4. Accelerated migration of APCs into dLNs in the presence of NAFL/IMIQ**  
MHC II-EGFP transgenic mice were ID inoculated in one ear with influenza vaccine adjuvanted with NAFL or NAFL/IMIQ. Accumulation of MHC II<sup>+</sup> APCs around individual MTZs was visualized by intravital confocal microscopy at varying times after immunization and the one captured at 8 hours post-immunization was shown in (a), left panel. A representative MTZ was tracked at 0, 3, 8, and 24 hours after immunization of influenza vaccine with NAFL treatment (upper panel) or NAFL/IMIQ (lower panel) in (a), representative of 6 similar results in two separate experiments. White dash circles highlight MTZs. Scale bar, 200  $\mu$ m. (b) Monitoring APCs within lymphatic vessels. Ears were prepared and stained by whole mount immunohistology 8 hours post-immunization. APCs (green), lymphatic vessels (blue and/or red), and blood vessels (red) were visualized by confocal microscopy, representative of 6 similar results in two separate experiments. Scale Bar, 100  $\mu$ m. Average numbers of APCs within each lymphatic vessel were determined by manual counting GFP<sup>+</sup> cells inside the lymphatic vessels in 20 randomly selected fields with a total of more than 40 lymphatic vessels counted (c) during which three-D scanning was performed to confirm the intra-vessel localization of each APC (b). (d, e) Proportions of CD11<sup>+</sup> DCs in the skin (d) and a total number of DCs in each dLN (e). CD11<sup>+</sup> DCs in the dorsal skin and dLNs were quantified by flow cytometry at indicated times after immunizing with the influenza vaccine alone or in the presence of indicated adjuvants as Fig. 1. n=6, except for NAFL/IMIQ group (n=8). Data are presented as mean  $\pm$  s.e.m. Statistical

significance was analyzed by ANOVA/Bonferroni. \*,  $p < 0.05$ ; \*\*,  $p < 0.01$  or \*\*\*,  $p < 0.001$ , respectively. All experiments were repeated twice with similar results.



**Figure 5. NAFL/IMIQ preferably recruits pDCs**

(a) Chemokine production at the inoculation site. The levels of indicated chemokines were measured in BALB/c mice after varying times of laser treatment by quantitative real-time PCR (qPCR), normalized to GAPDH, and expressed as fold increases relatively to time zero. Each square represents the mean value of 4 mice and color indicates a fold increase from low (blue) to high (red). (b) Recruitment of pDCs into the inoculation site. pDCs were identified by B220<sup>+</sup>CD11b<sup>+</sup>PCDA-1<sup>+</sup>Ly6C<sup>+</sup> cells by flow cytometry as described in Supplementary Fig. 6 and the percentages of pDCs in total skin cells were determined 6 and 24 hours after vaccination with influenza vaccine alone or in the presence of indicated adjuvants. n=4. (c) The inoculation sites were also stained with siglec H-specific antibody (upper panel) or isotype control antibody (lower panel) 24 hours after NAFL/IMIQ treatment. Note: Siglec H staining (red) was concentrated around MTZ (white dish lines). Representative results of 6 similar samples in two separate experiments. Blue, DAPI staining of cell nuclei. Scale bar, 100  $\mu$ m. Insets in (c) show a MTZ (white dish line), part of which is outlined by a white square and enlarged in C. (d) Cytokine expression at the inoculation sites 6 hours after immunization. The expression levels of indicated cytokines were measured by qPCR and expressed as fold increases relative to those in the mice receiving no adjuvant. Each square represents a mean of 4 mice. (e, f) Increases in the number numbers of mature DCs in dLNs in mice receiving influenza vaccine and NAFL/IMIQ. dLNs were collected at indicated times after immunization and mature DCs were identified as CD86<sup>+</sup>CD11c<sup>+</sup> cells (e) or CD40<sup>+</sup>CD11c<sup>+</sup> cells (f). n=6, except for the NAFL/

IMIQ group (n=8). (g) Effects of pDC depletion on NAFL/IMIQ-mediated adjuvanticity. Mice were IP injected with 400  $\mu$ g anti-mPDCA-1 antibody or control antibodies (control) at 24 and 0 hour before immunization. One week later cellular immune responses were measured (middle and lower panel), and humoral immune responses were measured two weeks later (upper panel). n=8. Data are presented as mean  $\pm$  s.e.m. Statistical significance was analyzed by ANOVA/Bonferroni. \*, p<0.05; \*\*, p<0.01 or \*\*\*, p<0.001, respectively. All experiments were repeated twice with similar results.


Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript





**Figure 6. NAFL/IMIQ augments protective immunity in old mice**

Old BALB/c mice were ID immunized with 0.6  $\mu$ g (HA content) H1N1 influenza vaccine alone or in the presence of NAFL, IMIQ, or NAFL/IMIQ adjuvant. IM immunizations with a same dose of the vaccine mixed with AddaVax adjuvant in old mice or without AddaVax (AddaVax) in both old (IM) and adult (adult IM) mice were used as controls. (a) HAI antibody titers were measured 4 weeks later. Percentages of IFN $\gamma$ -secreting CD4 $^{+}$  (b) and CD8 $^{+}$  (c) T cells were analyzed in vaccine-stimulated PBMCs one week after the immunizations. Mice were challenged in 5 weeks with 5 $\times$  LD $_{50}$  of mouse-adapted A/California/7/2009 H1N1 viruses. Body weight (d) and survival (e) were monitored daily for 16 days after challenge. n= 6, except for the NAFL/IMIQ group (n=13). Data are presented as mean  $\pm$  s.e.m. Statistical significance was analyzed by ANOVA/Dunnett's. \*, p<0.05; \*\*, p< 0.01 or \*\*\*, p< 0.001, respectively. All experiments were repeated twice with similar results.